24/7 Market News Snapshot 19 March, 2025 – Black Diamond Therapeutics, Inc. Common Stock (NASDAQ:BDTX)

March 19, 2025

DENVER, Colo., 19 March, 2025 (247marketnews.com) – (NASDAQ:BDTX) are discussed in this article.
Black Diamond Therapeutics, Inc. is witnessing a significant upswing in its stock price, highlighted by a notable 24.35% increase to $2.089 in pre-market trading. This surge, supported by a trading volume of 2.65 million shares, reflects strong investor interest and a positive market sentiment towards the company’s innovative therapeutics pipeline. The robust performance of Black Diamond shares offers an enticing opportunity for investors looking to participate in the biotechnology sector’s growth.

Concurrently, Black Diamond has announced a strategic partnership with Servier, a global pharmaceutical group specializing in oncology. This collaboration focuses on advancing BDTX-4933, a Phase 1 small molecule therapy designed to target RAS mutations and RAF alterations found in solid tumors, including non-small cell lung cancer (NSCLC). The partnership aims to leverage Servier’s expertise in oncology to enhance the development and commercialization of this promising treatment, which could significantly impact cancer care.

As part of the agreement, Black Diamond will receive an initial upfront payment of $70 million, with potential earnings of up to $710 million in milestone payments along with tiered royalties based on global net sales. Currently in the dose escalation and expansion phase of clinical trials, BDTX-4933 is being evaluated for its safety, tolerability, and preliminary efficacy in patients with advanced and metastatic cancers.

Mark Velleca, M.D., Ph.D., President and CEO of Black Diamond, emphasized the importance of this collaboration in fulfilling their mission to provide innovative cancer therapies. Servier’s Executive Vice-President of R&D, Claude Bertrand, echoed this sentiment, underscoring the potential of BDTX-4933 to deliver tailored treatment solutions and enhance patient outcomes. This partnership not only signifies a pivotal step for Black Diamond Therapeutics but also contributes to the evolution of precision medicine in the oncology field.

Related news for (BDTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.